Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo.
We examined the effect of interleukin-15 (IL-15) gene transfer into tumour cells on the host's anti-tumour response. In BALB/c mice IL-15 producing Meth-A cells (Meth-A/IL-15) underwent complete rejection, in a response characterized by massive infiltration of CD4+ T-cells and neutrophils. In contrast, Meth-A cells transfected with vector alone (Meth-A/Neo) grew rapidly. Moreover, rechallenged parental cells also were rejected in association with CD8* T-cell infiltration. However, in nude mice there was no drastic difference between Meth-A/IL-15 and Meth-A/Neo cells. These results demonstrate that IL-15-secreting tumour cells can stimulate local and systemic T-cell-dependent immunity and therefore may have a potential role in cancer therapy.
Hazama
S
S
Department of Surgery II, Yamaguchi University School of Medicine, Ube, Japan.
Noma
T
T
Wang
F
F
Iizuka
N
N
Ogura
Y
Y
Yoshimura
K
K
Inoguchi
E
E
Hakozaki
M
M
Hirose
K
K
Suzuki
T
T
Oka
M
M
D000818:Animals; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D019409:Interleukin-15 / Q000235:genetics*; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D014162:Transfection
D019409:Interleukin-15